Subjects:
BloodWork, Free Research Articles, Lymphoid Neoplasia, Multiple Myeloma, Myeloid Neoplasia
Topics:
immunoglobulin d, multiple myeloma, myelodysplastic syndrome
An 82-year-old woman presented with left-hip pain. Radiographs revealed multiple bone lesions in the skull and left acetabulum. Laboratory tests showed a peak of monoclonal immunoglobulin D (IgD) κ at 5.1 g/L; albumin, 23 g/L; and hemoglobin, 9 g/dL. Other parameters were normal. Bone marrow showed involvement with 76% dysplastic plasma cells (panels A-B, F; May-Grünwald Giemsa stain, original magnifications ×100 [A-B] and ×63 [F]), associated with dysplasia in hematopoietic lineages, characterized by agranular and hyposegmented neutrophils (panel B), acidophilic erythroblasts with an irregular nucleus (panel C; May-Grünwald Giemsa stain, original magnification ×100), degranulated neutrophilic metamyelocytes and dwarf degranulated neutrophils (panel D; May-Grünwald Giemsa stain, original magnification ×100), cellular gigantism (panel E; May-Grünwald Giemsa stain, original magnification ×50), and a binucleated megakaryocyte (panel F).The karyotype was complex with hyperploidy. Fluorescence in situ hybridization showed an MYC rearrangement in 8q24 in 34% of the plasmocytes. Immunophenotyping of bone marrow showed CD71 (+149%), CD36 (+96%), and an Ogata score of 2. Next generation sequencing of the bone marrow revealed a TET2 nonsense mutation. An IgD κ International Staging System for Multiple Myeloma (ISS) score of 2 and standard-risk cytogenetics associated with refractory cytopenia with multilineage dysplasia were confirmed. / The patient was treated with a bortezomib (Velcade)-melphalan-dexamethasone regimen, consisting of 9 cycles, plus erythropoietin, and achieved very good partial response without an increase of cytopenia. IgD κ subtype myeloma is a very rare disease. However, the outcome appears to be affected by the ISS score, cytogenetic risk, and the type of treatment, as it is for other isotypes.
View largeDownload PPT

An 82-year-old woman presented with left-hip pain. Radiographs revealed multiple bone lesions in the skull and left acetabulum. Laboratory tests showed a peak of monoclonal immunoglobulin D (IgD) κ at 5.1 g/L; albumin, 23 g/L; and hemoglobin, 9 g/dL. Other parameters were normal. Bone marrow showed involvement with 76% dysplastic plasma cells (panels A-B, F; May-Grünwald Giemsa stain, original magnifications ×100 [A-B] and ×63 [F]), associated with dysplasia in hematopoietic lineages, characterized by agranular and hyposegmented neutrophils (panel B), acidophilic erythroblasts with an irregular nucleus (panel C; May-Grünwald Giemsa stain, original magnification ×100), degranulated neutrophilic metamyelocytes and dwarf degranulated neutrophils (panel D; May-Grünwald Giemsa stain, original magnification ×100), cellular gigantism (panel E; May-Grünwald Giemsa stain, original magnification ×50), and a binucleated megakaryocyte (panel F).The karyotype was complex with hyperploidy. Fluorescence in situ hybridization showed an MYC rearrangement in 8q24 in 34% of the plasmocytes. Immunophenotyping of bone marrow showed CD71 (+149%), CD36 (+96%), and an Ogata score of 2. Next generation sequencing of the bone marrow revealed a TET2 nonsense mutation. An IgD κ International Staging System for Multiple Myeloma (ISS) score of 2 and standard-risk cytogenetics associated with refractory cytopenia with multilineage dysplasia were confirmed.

The patient was treated with a bortezomib (Velcade)-melphalan-dexamethasone regimen, consisting of 9 cycles, plus erythropoietin, and achieved very good partial response without an increase of cytopenia. IgD κ subtype myeloma is a very rare disease. However, the outcome appears to be affected by the ISS score, cytogenetic risk, and the type of treatment, as it is for other isotypes.

An 82-year-old woman presented with left-hip pain. Radiographs revealed multiple bone lesions in the skull and left acetabulum. Laboratory tests showed a peak of monoclonal immunoglobulin D (IgD) κ at 5.1 g/L; albumin, 23 g/L; and hemoglobin, 9 g/dL. Other parameters were normal. Bone marrow showed involvement with 76% dysplastic plasma cells (panels A-B, F; May-Grünwald Giemsa stain, original magnifications ×100 [A-B] and ×63 [F]), associated with dysplasia in hematopoietic lineages, characterized by agranular and hyposegmented neutrophils (panel B), acidophilic erythroblasts with an irregular nucleus (panel C; May-Grünwald Giemsa stain, original magnification ×100), degranulated neutrophilic metamyelocytes and dwarf degranulated neutrophils (panel D; May-Grünwald Giemsa stain, original magnification ×100), cellular gigantism (panel E; May-Grünwald Giemsa stain, original magnification ×50), and a binucleated megakaryocyte (panel F).The karyotype was complex with hyperploidy. Fluorescence in situ hybridization showed an MYC rearrangement in 8q24 in 34% of the plasmocytes. Immunophenotyping of bone marrow showed CD71 (+149%), CD36 (+96%), and an Ogata score of 2. Next generation sequencing of the bone marrow revealed a TET2 nonsense mutation. An IgD κ International Staging System for Multiple Myeloma (ISS) score of 2 and standard-risk cytogenetics associated with refractory cytopenia with multilineage dysplasia were confirmed. / The patient was treated with a bortezomib (Velcade)-melphalan-dexamethasone regimen, consisting of 9 cycles, plus erythropoietin, and achieved very good partial response without an increase of cytopenia. IgD κ subtype myeloma is a very rare disease. However, the outcome appears to be affected by the ISS score, cytogenetic risk, and the type of treatment, as it is for other isotypes.
View largeDownload PPT

An 82-year-old woman presented with left-hip pain. Radiographs revealed multiple bone lesions in the skull and left acetabulum. Laboratory tests showed a peak of monoclonal immunoglobulin D (IgD) κ at 5.1 g/L; albumin, 23 g/L; and hemoglobin, 9 g/dL. Other parameters were normal. Bone marrow showed involvement with 76% dysplastic plasma cells (panels A-B, F; May-Grünwald Giemsa stain, original magnifications ×100 [A-B] and ×63 [F]), associated with dysplasia in hematopoietic lineages, characterized by agranular and hyposegmented neutrophils (panel B), acidophilic erythroblasts with an irregular nucleus (panel C; May-Grünwald Giemsa stain, original magnification ×100), degranulated neutrophilic metamyelocytes and dwarf degranulated neutrophils (panel D; May-Grünwald Giemsa stain, original magnification ×100), cellular gigantism (panel E; May-Grünwald Giemsa stain, original magnification ×50), and a binucleated megakaryocyte (panel F).The karyotype was complex with hyperploidy. Fluorescence in situ hybridization showed an MYC rearrangement in 8q24 in 34% of the plasmocytes. Immunophenotyping of bone marrow showed CD71 (+149%), CD36 (+96%), and an Ogata score of 2. Next generation sequencing of the bone marrow revealed a TET2 nonsense mutation. An IgD κ International Staging System for Multiple Myeloma (ISS) score of 2 and standard-risk cytogenetics associated with refractory cytopenia with multilineage dysplasia were confirmed.

The patient was treated with a bortezomib (Velcade)-melphalan-dexamethasone regimen, consisting of 9 cycles, plus erythropoietin, and achieved very good partial response without an increase of cytopenia. IgD κ subtype myeloma is a very rare disease. However, the outcome appears to be affected by the ISS score, cytogenetic risk, and the type of treatment, as it is for other isotypes.

Close modal

For additional images, visit the ASH IMAGE BANK, a reference and teaching tool that is continually updated with new atlas and case study images. For more information visit http://imagebank.hematology.org.

© 2017 by The American Society of Hematology
2017
Sign in via your Institution